Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131523) titled 'A Phase III, randomized, open-label, multicenter study evaluating the effectiveness and safety of cevostamab combined with pomalidomide and dexamethasone versus standard care in patients with multiple' on Sept. 3.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Zhongshan Hospital, Fudan University
Condition:
Multiple myeloma
Intervention:
Test group:Cevostamab in combination with pomalidomide and dexamethasone
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-09-18
Target Sample Size: Test group:190;Control group:190;
Countries of Recruitment:
Chi...